Efficacy and safety of once-weekly Tirzepatide, a dual GIP/GLP-1 receptor agonist vs. placebo as monotherapy in people with type 2 diabetes (SURPASS-1)

With the increasing prevalence of diabetes, new treatment approaches are in need of time. Rosenstock J and colleagues conducted research under the title “Efficacy and safety of once-weekly Tirzepatide, a dual GIP/GLP-1 receptor agonist vs. placebo as monotherapy in people with type 2 diabetes (SURPASS-1)”. The summary of this study is given below:

Objective:

To investigate the efficacy and safety of tirzepatide (TZP) in people with T2D.

Method:

People with a mean T2D duration of 4.7yr with HbA1c of 7.94%, BMI 31.9 Kg/m2 were included in this double-blind, placebo (PBO) controlled, 40-week phase 3 study. Patients were randomized to TZP or PBO. The main outcome was a mean change in HbA1c from baseline. Mean change in fasting serum glucose (FSG) and body weight (BW) were the secondary outcomes.

Findings:

The study found that TZB 5, 10, and 15 mg positively associated with achieving HbA1c <7.0% and <5.7% as compare to PBO. TZB was also found to be effective in BW loss. TZB was reported to be well tolerated with the most common adverse effect being mild to moderate gastrointestinal complaints. There was no severe hypoglycemia reported with TZB.

Image Credit : Hand photo created by jcomp – www.freepik.com